2026 Volume 49 Issue 11 Pages 1915-1922
Although potassium binders may reduce the absorption of orally administered cationic opioids in the intestinal lumen, their clinical impact is unknown. This study aimed to clarify the effects of the concomitant use of potassium binders on opioid dosage and analgesic efficacy. A single-institution retrospective cohort study was conducted with 112 adult patients who received oral opioids and initiated potassium binders. The primary outcome was a change in the maximum scheduled opioid dose before and after potassium binder initiation. Oxycodone-equivalent doses (strong opioid cohort) and tramadol doses (weak opioid cohort) were compared. Factors associated with strong scheduled opioid dose escalation were assessed using univariate logistic regression. Of the 112 patients, 66 patients comprised the strong opioid cohort and 46 patients comprised the weak opioid cohort. In the strong opioid cohort, the maximum scheduled opioid dose significantly increased after potassium binder initiation (p = 0.022), whereas no significant change was observed in the weak opioid cohort (p = 0.978). Univariable logistic regression identified age <65 years (odds ratio [OR]: 3.71; 95% confidence interval [CI]: 1.06–15.2; p = 0.040), aspartate aspartate aminotransferase (OR: 1.02; 95% CI: 1.01–1.04; p = 0.013), and oxycodone-equivalent scheduled doses ≥25 mg/d (OR: 4.45; 95% CI: 1.25–16.6; p = 0.022), particularly ≥80 mg/d (OR: 7.66; 95% CI: 1.70–37.4; p = 0.009) as factors associated with scheduled dose escalation. Concomitant use of potassium binders may be associated with reduced strong opioid analgesic efficacy. Age <65 years, elevated aspartate aminotransferase and oxycodone-equivalent scheduled doses ≥25 mg/d were considered factors associated with scheduled opioid dose escalation.